JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

GOLDEN MOLECULES — THE BIOAVAILABILITY PUZZLE OF CURCUMIN

Author: ***Km Shaheen, Dr. Prakash Deep, Dr. Shikhar Verma***

Maharishi School of Pharmaceutical Sciences, MUIT, Lucknow

Abstract
Curcumin, the main curcuminoid in turmeric (*Curcuma longa*), has gotten a lot of attention from scientists because it has been linked to many biological activities, such as being anti-inflammatory, antioxidant, anticancer, neuroprotective, and beneficial for metabolism. Despite strong preclinical evidence, curcumin's poor oral bioavailability, fast metabolism, and limited tissue distribution have made it hard to use in clinical settings. This review consolidates contemporary insights into curcumin's chemistry and pharmacology, elucidating the mechanistic underpinnings of its low bioavailability and contemporary strategies devised to mitigate these challenges, encompassing formulation techniques (nanoparticles, liposomes, micelles, solid dispersions), adjuvants (piperine), and structural analogues. The article also looks at pharmacokinetic data in a critical way, talks about ways to measure curcumin and its metabolites, looks at safety and tolerability, and points out gaps in knowledge and future directions that could speed up the process of making curcumin into a medicine.

Keywords: Curcumin, bioavailability, pharmacokinetics, nanoparticles, liposomes, piperine, metabolism, curcuminoids, delivery systems

1. Introduction

Curcumin, a polyphenolic compound that gives turmeric its yellow colour, has been used in traditional medicine for hundreds of years. Contemporary research has unveiled an extraordinary array of biological activities both in vitro and in animal models. Nevertheless, excitement surrounding curcumin as a therapeutic agent has been moderated by pharmacokinetic obstacles: orally administered curcumin exhibits low plasma concentrations, significant first-pass metabolism, and swift systemic elimination. These limitations give rise to an essential research inquiry: how can we convert curcumin from a potentially beneficial laboratory compound into a clinically effective pharmaceutical? This review presents the issue as a "bioavailability puzzle" and methodically analyses the chemical, biological, and technological components that must align to resolve it.

2. Chemical structure and physicochemical properties

Curcumin (diferuloylmethane) is a diarylheptanoid that has two aromatic ring systems with o-methoxy phenolic groups connected by a seven-carbon linker with an α, β-unsaturated β-diketone moiety. This structure gives rise to several properties that are important for absorption and metabolism:

- **Hydrophobicity:** Low water solubility (less than 0.1 mg/mL), which makes it hard to dissolve in fluids in the stomach and intestines.
- **Chemical instability:** It is sensitive to alkaline pH and breaks down quickly through hydrolysis and oxidation, which makes less of it available for absorption.
- **Conjugation sites:** The β-diketone and phenolic hydroxyls are the targets for phase II metabolism (glucuronidation and sulfation).
- **Lipophilicity:** A high log P (about 2.5–3.0) makes it easier for the drug to cross membranes and bind strongly to plasma proteins and the intestinal mucosa.

These inherent properties help explain the low systemic exposure seen after oral ingestion and underscore why formulation and chemical modification strategies aim to increase solubility, protect curcumin from degradation, and modulate metabolic fate.

3. Pharmacokinetics and disposition

3.1 Absorption

Curcumin has inconsistent and poor absorption when taken orally. Only a small portion of the administered dose is detectable in plasma, according to research on both humans and animals. Poor dissolution in the gut lumen and metabolization/degradation in enterocytes and lumenal environments limit absorption.

3.2 Dispersal

When detected, curcumin spreads widely throughout tissues; however, quantifiable systemic concentrations are frequently low in relation to doses given. High affinity for plasma proteins, such as albumin, can affect tissue penetration and free fraction.

3.3 Elimination and metabolism

Curcumin is extensively metabolised in phases I and II. Polar metabolites that are quickly removed in bile and urine are produced by rapid reduction (to tetrahydrocurcumin and hexahydrocurcumin) and conjugation (mainly glucuronidation and sulfation). Enterohepatic recycling of conjugates and possible microbial metabolism in the gut add complexity to its disposition.

3.4 Bioavailability metrics

When comparing oral and IV administration, the absolute oral bioavailability is extremely low; even after gram-scale oral doses, many human studies show plasma Cmax frequently falls below 1 µg/mL. Short half-life (often less than a few hours for unconjugated curcumin), quick Tmax (1-2 hours), and a large apparent volume of distribution in certain animal models are important pharmacokinetic parameters.

4. Curcumin and its metabolites measurement.

For PK studies and formulation strategy validation, precise quantification of curcumin and its metabolites is crucial. LC-MS/MS, HPLC-UV, and HPLC-MS/MS are examples of analytical techniques. Challenges include: • Processing instability: samples need to be processed fast and frequently call for stabilisers or low temperatures because curcumin can degrade.

- **Matrix effects:** The components of bile and plasma proteins make extraction and quantification more difficult.
- **Identification of metabolites:** Targeted MS/MS techniques or enzymatic deconjugation are frequently needed for conjugated metabolites.

Methodological consistency across studies is limited, contributing to variability in reported pharmacokinetic values.

5. Mechanistic basis for poor bioavailability

The low systemic exposure of curcumin results from several interacting factors:

1. Low aqueous solubility and rate of dissolution—reduces the amount of dose that can be absorbed.
2. Chemical instability in the gastrointestinal tract: curcumin can degrade into products under alkaline conditions.
3. The amount of free curcumin that enters the bloodstream is decreased by extensive intestinal and hepatic metabolism, specifically the quick glucuronidation and sulfation that occur in enterocytes and hepatocytes.
4. Efflux transporters: P-glycoprotein and additional transporters may actively return curcumin and its metabolites to the intestinal lumen.
5. Biliary excretion and first-pass elimination—metabolites are eliminated rapidly.

One or more of these steps must be addressed in any effective bioavailability enhancement strategy.

6. Formulation strategies to improve bioavailability

Numerous delivery methods have been investigated. Generally speaking, formulations seek to increase solubility, shield curcumin from deterioration, encourage intestinal absorption, and/or alter metabolism.

6.1 Adjuvant strategy: Piperine

Piperine, an alkaloid found in black pepper, decreases the conjugation of curcumin and increases systemic exposure by inhibiting UDP-glucuronosyltransferases and specific cytochrome P450 enzymes. Co-administration of piperine increased bioavailability by several times, according to a human study that is often cited. Benefits: easy and affordable. Limitations: wide-ranging CYP/UGT inhibition may result in drug-drug interactions.

6.2 Systems based on lipids: Solid lipid nanoparticles and liposomes

Curcumin's solubility is enhanced and its degradation is prevented by liposomal encapsulation and solid lipid nanoparticles. Liposomes can either be taken up by endocytosis or fuse with enterocyte membranes. Solid lipid nanoparticles offer controlled release and physical protection. Numerous studies on animals demonstrate improved tissue delivery and elevated plasma levels.

6.3 Micelles and polymeric nanoparticles

Curcumin can be encapsulated in nanoparticles or micelles made of biodegradable polymers (PLGA, PEG-PLGA, and chitosan), which improves solubility and offers sustained release. Surface alterations, such as PEGylation, can decrease opsonisation and increase mucus penetration. Micellar systems can improve intestinal transit and significantly increase apparent aqueous solubility.

6.4 Complexes of phospholipids (phytosomes)

Curcumin improves uptake by enhancing lipophilicity and membrane interaction when complexed with phospholipids. This method is used in a number of commercially available supplements, with some evidence of increased plasma concentrations.

6.5 Cyclodextrin inclusion complexes

Cyclodextrins have the ability to encapsulate hydrophobic curcumin molecules within their hydrophobic cavity, thereby increasing their solubility in water. Optimisation of complexation stability and release rate is necessary.

6.6 Solid dispersions and micronization

Reducing particle size (micronization, nanosizing) increases surface area and dissolution rate. Solid dispersions with hydrophilic carriers enhance wettability and dissolution.

6.7 Co-crystals and prodrugs

Co-crystallization can alter metabolic pathways and increase stability when done with the right molecular partners and prodrug techniques. Prodrugs can be made to avoid first-pass metabolism or to release curcumin after absorption.

6. Evaluation of formulation strategies' comparative pharmacokinetic results

Several formulations demonstrate notable improvements in PK metrics when compared to unformulated curcumin, despite the paucity of head-to-head clinical comparisons:

- Curcumin + piperine: Several-fold increases in plasma AUC and Cmax were reported.
- Liposomal and nanoparticle formulations: Depending on the system and the ratio of free to total curcumin, these formulations can have variable but frequently significant increases in bioavailability (10–100× in some reports).
- Phospholipid complexes and phytosomes: Modest enhancements in tissue distribution and plasma exposure.
- Micronised and nanoemulsions: According to multiple studies, improved dissolution results in higher Cmax and AUC.

Different analytical techniques (free curcumin vs. conjugates), doses, species differences, and small sample sizes all make interpretation more difficult. However, recurring patterns show that bioavailability can be significantly increased with the right formulation.

7. Biological activity: metabolites versus free curcumin

Whether the biological effects of curcumin are dependent on the parent molecule or can be mediated by metabolites like tetrahydrocurcumin (THC), glucuronides, and sulphates is a crucial and occasionally overlooked question. A few points:

- **Active metabolites:** Certain metabolites, like tetrahydrocurcumin, maintain their biological and antioxidant properties and may have systemic effects.
- **Conjugates:** Although glucuronide and sulphate conjugates are frequently less active in vitro, tissue sulfatases and β-glucuronidases may be able to deconjugate them in vivo and restore local active curcumin.
- **Local vs systemic effects:** High intestinal exposure, even with low plasma levels, could mediate local GI benefits.

While increasing the parent compound's systemic levels is one objective, the therapeutic value of metabolites points to other approaches that take advantage of metabolite activity or targeted tissue delivery.

8. Therapeutic potential and clinical evidence

Clinical studies of curcumin, which is frequently found in formulated products or nutritional supplements, have looked at a variety of indications, such as neurological disorders, metabolic disorders, inflammatory diseases, and cancer adjunct therapy. Mixed results are obtained:

- **Positive signals:** A number of studies report favourable metabolic effects, decreases in inflammatory markers, and symptomatic improvement (such as less pain from osteoarthritis).
- **Negative or inconclusive trials:** Other research indicates little to no benefit. Interpretation is made more difficult by heterogeneity in formulations, dosages, patient populations, and outcome measures.

The use of formulations with unclear or low bioavailability, small sample sizes, and brief durations is a common limitation found in many clinical studies. Well-powered, PK-informed trials using bioavailable formulations are needed to clarify clinical efficacy.

9. Safety and tolerability

At typical supplemental dosages, curcumin is generally well tolerated by humans, with rare reports of mild side effects like gastrointestinal distress. Careful consideration of off-target effects and interactions is necessary when using higher dosages and formulations with improved bioavailability:

- **Interactions between drugs:** Drugs metabolised by CYPs or UGTs may interact with co-administered piperine or formulations that change metabolism.
- **Long-term security:** There is currently little information available on the long-term use of high-bioavailability products. When employing improved formulations in clinical settings, particularly in situations involving polypharmacy, a risk-benefit analysis is crucial.

10. Realistic issues for researchers and medical professionals

- **Describe the analyte:** Standardise procedures and choose whether to measure free curcumin, total curcumin (after deconjugation), or particular metabolites.
- **Transparency in formulation:** Provide a thorough description of the composition and production processes so that research can be compared.
- **Dose selection:** Utilize PK data to select doses expected to achieve relevant exposure.
- **Endpoints:** Combine biomarker endpoints with clinical outcomes and link exposure to pharmacodynamic effects.

Below are suggested tables and figure placeholders to include in a manuscript. (Graphs are described; high-quality plots can be generated using standardized PK datasets.)

Table 1 — Physicochemical properties of curcumin (summary)

Property	Value / description
Molecular formula	$C_{21}H_{20}O_6$
Molecular weight	368.38 g/mol
Log P	~2.5–3.0 (estimated)
Water solubility	<0.1 mg/mL (very low)
pKa	phenolic ~8–10 (approximate)
Stability	Unstable at alkaline pH; susceptible to oxidation

Table 2 — Key metabolic pathways and major metabolites

Pathway	Major metabolites	Notes
Reduction	tetrahydrocurcumin (THC), hexahydrocurcumin	May retain biological activity
Conjugation	curcumin-glucuronide, curcumin-sulfate	Major circulating forms after oral dosing
Degradation	ferulic acid, vanillin (degradation products)	Formed under alkaline/oxidative conditions

Table 3 — Representative PK outcomes from selected formulations (Illustrative)

Formulation	Species / Study	Dose (oral)	Change vs unformulated (Cmax / AUC)
Unformulated curcumin	Human	2 g	Baseline (low)
Curcumin + piperine	Human	2 g + 20 mg piperine	↑ Cmax, ↑ AUC (several-fold)
Liposomal curcumin	Animal / Human	variable	↑ 5–50× depending on system
Nanoparticle curcumin	Animal	variable	↑ 10–100× (depending on metrics)

Note: values are illustrative; analytical methods vary across studies.



Figure 1 — *Schematic of curcumin absorption, metabolism, and elimination*

Description: A flow diagram showing oral curcumin administration → dissolution in gut lumen → intestinal absorption → phase II metabolism in enterocytes (glucuronidation/sulfation) → portal circulation → hepatic metabolism → systemic circulation (parent + metabolites) → biliary/urinary excretion. Include efflux transporters and gut microbiome metabolism as modulators.

Figure 2 — *Conceptual comparison of formulation strategies*

Description: A conceptual bar chart comparing relative improvements in systemic exposure (Cmax/AUC) for major formulation categories: piperine co-administration, liposomes, polymeric nanoparticles, phytosomes, micronized powders. Bars represent relative qualitative improvements (low/moderate/high) with annotation of main advantages and limitations.



Figure 3 — *Example pharmacokinetic curve*

Description: Plots of plasma concentration vs time for unformulated curcumin (low peak, fast decline) vs a nanoformulation (higher peak, prolonged exposure). Include separate curves for free curcumin and total curcumin (after deconjugation) to highlight measurement differences.

11. Critical gaps and future perspectives

Despite extensive research, several knowledge gaps remain:

1. **Standardised analytical techniques:** It's necessary to use consistent measurement techniques for free and conjugated curcumin.
2. **Head-to-head clinical trials:** Evaluations of formulations in order to determine the most effective clinical strategies.
3. **Recognising active species:** Identify the molecular species that mediate important therapeutic effects (parent curcumin versus metabolites).
4. **Long-term safety data:** For formulations with high bioavailability, particularly when metabolic pathways are altered.
5. **Targeted delivery:** Improvement and clinical translation are required for tissue- or cell-specific delivery (e.g., to the brain or tumour microenvironment).
6. **Microbiome interactions:** The function of gut microorganisms in the metabolism of curcumin and the impact of formulations on microbial changes.

Some promising approaches include microbially-targeted formulations that use gut metabolism to produce active metabolites locally, multi-modal systems that combine metabolic inhibitors and solubility enhancement in a controlled way, and logical prodrug design that avoids first-pass conjugation.

12. Conclusions

Curcumin posses a significant bioavailability challenge in addition to being an intriguing therapeutic candidate. Systemic exposure following oral dosing is limited by the compound's physicochemical characteristics and quick metabolism; however, contemporary pharmaceutical techniques, ranging from straightforward adjuvants like piperine to sophisticated nanoparticulate systems, can significantly raise plasma and tissue levels. Thorough, PK-guided trials employing well-described formulations and standardised analytical techniques are necessary for translation to clinical benefit. Crucially, development strategies should incorporate the therapeutic role of curcumin's metabolites. A multifaceted strategy combining creative chemistry, customised delivery systems, and meticulous clinical research is probably needed to solve the curcumin bioavailability conundrum.

Acknowledgements

I, Km. Shaheen sincerely acknowledge the guidance, encouragement, and constructive feedback received throughout the preparation of this review paper. Special thanks are extended to mentors, colleagues, and peers who provided valuable insights and critical suggestions that strengthened the quality of this work. The author also expresses gratitude to the researchers and scholars whose published works formed the foundation of this review. Finally, heartfelt appreciation goes to family and friends for their constant support and encouragement during the writing process.

References

Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. *Molecular Pharmaceutics, 4*(6), 807–818. https://doi.org/10.1021/mp700113r

Asai, A., & Miyazawa, T. (2000). Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. *Life Sciences, 67*(23), 2785–2793. https://doi.org/10.1016/S0024-3205(00)00868-7

Belcaro, G., Cesarone, M. R., Dugall, M., Pellegrini, L., Ledda, A., Grossi, M. G., Togni, S., & Appendino, G. (2010). Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. *Alternative Medicine Review, 15*(4), 337–344.

Daily, J. W., Yang, M., & Park, S. (2016). Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: A systematic review and meta-analysis of randomized clinical trials. *Journal of Medicinal Food, 19*(8), 717–729. https://doi.org/10.1089/jmf.2016.3705

Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013). Therapeutic roles of curcumin: Lessons learned from clinical trials. *The AAPS Journal, 15*(1), 195–218. https://doi.org/10.1208/s12248-012-9432-8

Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A review of its' effects on human health. *Foods, 6*(10), 92. https://doi.org/10.3390/foods6100092

Howells, L. M., Iwuji, C. O. O., & Perry, S. L. (2007). The impact of curcumin and piperine on human pharmacokinetics of curcumin in healthy volunteers. *Cancer Chemotherapy and Pharmacology, 60*(2), 171–177. https://doi.org/10.1007/s00280-006-0355-x

Huang, M. T., Lysz, T., Ferraro, T., Abidi, T. F., Laskin, J. D., & Conney, A. H. (1991). Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. *Cancer Research, 51*(3), 813–819.

Ireson, C. R., Jones, D. J. L., Orr, S., Coughtrie, M. W. H., Boocock, D. J., Williams, M. L., ... & Steward, W. P. (2001). Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. *Cancer Epidemiology, Biomarkers & Prevention, 10*(5), 507–513.

Kumar, V., Lewis, S. A., Mutalik, S., Shenoy, D. B., & Udupa, N. (2000). Biodegradable microspheres of curcumin for treatment of inflammation. *Indian Journal of Experimental Biology, 40*(11), 1171–1175.

Kunnumakkara, A. B., Bordoloi, D., Harsha, C., Banik, K., Gupta, S. C., & Aggarwal, B. B. (2017). Curcumin mediates anticancer effects by modulating multiple cell signaling pathways. *Clinical Science, 131*(15), 1781–1799. https://doi.org/10.1042/CS20160935

Lao, C. D., Ruffin, M. T., Normolle, D., Heath, D. D., Murray, S. I., Bailey, J. M., ... & Brenner, D. E. (2006). Dose escalation of a curcuminoid formulation. *BMC Complementary and Alternative Medicine, 6*(1), 10. https://doi.org/10.1186/1472-6882-6-10

Maiti, K., Mukherjee, K., Gantait, A., Saha, B. P., & Mukherjee, P. K. (2007). Curcumin–phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. *International Journal of Pharmaceutics, 330*(1-2), 155–163. https://doi.org/10.1016/j.ijpharm.2006.09.025

Marczylo, T. H., Steward, W. P., & Gescher, A. J. (2007). Rapid screening of curcumin conjugates in human plasma by LC-MS/MS. *Journal of Agricultural and Food Chemistry, 55*(3), 895–902. https://doi.org/10.1021/jf062653x

Pan, M. H., Huang, T. M., & Lin, J. K. (1999). Biotransformation of curcumin through reduction and glucuronidation in mice. *Drug Metabolism and Disposition, 27*(4), 486–494.

Patel, S. S., Raghuwanshi, R., Masood, M., Surendran, D., & Pandey, D. N. (2010). Curcumin delivery methods: A review. *Journal of Drug Delivery & Therapeutics, 2*(3), 111–118.

Pluta, R., Ułamek-Kozioł, M., & Januszewski, S. (2020). Curcumin and neuroprotection in the aging brain: An overview of the potential therapeutic effects. *International Journal of Molecular Sciences, 21*(15), 5645. https://doi.org/10.3390/ijms21155645

Prasad, S., Tyagi, A. K., & Aggarwal, B. B. (2014). Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: The golden pigment from golden spice. *Cancer Research and Treatment, 46*(1), 2–18. https://doi.org/10.4143/crt.2014.46.1.2

Priyadarsini, K. I. (2014). The chemistry of curcumin: From extraction to therapeutic agent. *Molecules, 19*(12), 20091–20112. https://doi.org/10.3390/molecules191220091

Shen, L., & Ji, H. F. (2012). The pharmacology of curcumin: Is it the degradation products? *Trends in Molecular Medicine, 18*(3), 138–144. https://doi.org/10.1016/j.molmed.2011.12.003

Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., & Srinivas, P. S. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Medica, 64*(4), 353–356. https://doi.org/10.1055/s-2006-957450

Siviero, A., Gallo, E., Maggini, V., Gori, L., Mugelli, A., Firenzuoli, F., & Vannacci, A. (2015). Curcumin, a golden spice with a low bioavailability. *Journal of Herbal Medicine, 5*(2), 57–70. https://doi.org/10.1016/j.hermed.2015.03.001

Sun, M., Su, X., Ding, B., He, X., Liu, X., Yu, A., & Lou, H. (2012). Advances in nanotechnology-based delivery systems for curcumin. *Nanomedicine: Nanotechnology, Biology and Medicine, 8*(6), 833–849. https://doi.org/10.1016/j.nano.2011.11.003

Wahlang, B., Pawar, Y. B., & Bansal, A. K. (2011). Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. *European Journal of Pharmaceutics and Biopharmaceutics, 77*(2), 275–282. https://doi.org/10.1016/j.ejpb.2010.11.003

Wang, Y. J., Pan, M. H., Cheng, A. L., Lin, L. I., Ho, Y. S., Hsieh, C. Y., & Lin, J. K. (1997). Stability of curcumin in buffer solutions and characterization of its degradation products. *Journal of Pharmaceutical and Biomedical Analysis, 15*(12), 1867–1876. https://doi.org/10.1016/S0731-7085(96)02024-9

Yallapu, M. M., Jaggi, M., & Chauhan, S. C. (2012). Curcumin nanoformulations: A future nanomedicine for cancer. *Drug Discovery Today, 17*(1-2), 71–80. https://doi.org/10.1016/j.drudis.2011.09.009